CliffBio
small molecule

VIREAD

TENOFOVIR DISOPROXIL FUMARATE

Loss of exclusivity—loss of exclusivity
CompanyGilead Sciences →See this company's full patent-cliff portfolio

Drug detail

Brand nameVIREAD
Active ingredientTENOFOVIR DISOPROXIL FUMARATE
Strength40MG/SCOOPFUL
Dosage formPOWDER
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2012
Marketing statusRX

More from Gilead Sciences

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.